Iovance Biotherapeutics Inc (NASDAQ:IOVA) Could Burn Your Long Portfolio After More Shorts

The stock of Iovance Biotherapeutics Inc (NASDAQ:IOVA) registered an increase of 3.55% in short interest. IOVA’s total short interest was 13.30M shares in September as published by FINRA. Its up 3.55% from 12.84 million shares, reported previously. With 1.95M shares average volume, it will take short sellers 7 days to cover their IOVA’s short positions.

The stock increased 3.74% or $0.77 during the last trading session, reaching $21.49. About 753,571 shares traded. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has risen 87.00% since September 13, 2018 and is uptrending. It has outperformed by 87.00% the S&P500.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company has market cap of $2.66 billion. The companyÂ’s lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes , which are T cells derived from patientsÂ’ tumors for the treatment of patients with refractory metastatic melanoma. It currently has negative earnings. It is also developing LN-145 to treat cervical and head and neck cancers.

More notable recent Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) news were published by: Globenewswire.com which released: “Iovance Biotherapeutics Announces First Patient Dosed in Cohort 4 of Pivotal InnovaTIL-01 Study of Lifileucel in Metastatic Melanoma – GlobeNewswire” on April 02, 2019, also Seekingalpha.com with their article: “Iovance Biotherapeutics Is The Next Biotech Takeover Candidate For Its Breakthrough TILs Technology – Seeking Alpha” published on June 13, 2019, Globenewswire.com published: “Iovance Biotherapeutics and MaSTherCell Announce New Manufacturing Services Agreement in Europe – GlobeNewswire” on October 18, 2018. More interesting news about Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) were released by: Seekingalpha.com and their article: “Iovance up 4% premarket on bullish registration path for LN-145 – Seeking Alpha” published on July 02, 2019 as well as Globenewswire.com‘s news article titled: “Iovance Biotherapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update – GlobeNewswire” with publication date: August 01, 2019.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.